Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

Author:

Sun Chaoyang12ORCID,Fang Yong1,Yin Jun1,Chen Jian13,Ju Zhenlin4ORCID,Zhang Dong1,Chen Xiaohua1,Vellano Christopher P.1,Jeong Kang Jin1,Ng Patrick Kwok-Shing5ORCID,Eterovic Agda Karina B.1,Bhola Neil H.6ORCID,Lu Yiling1,Westin Shannon N.7,Grandis Jennifer R.6ORCID,Lin Shiaw-Yih1,Scott Kenneth L.8,Peng Guang9,Brugge Joan10,Mills Gordon B.1

Affiliation:

1. Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

2. Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

3. Department of General Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Province, Hangzhou 310000, China.

4. Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

5. Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

6. Provost Office, University of California, San Francisco, San Francisco, CA 94158, USA.

7. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

8. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.

9. Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

10. Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA.

Abstract

The combination of PARP and MEK inhibitors is effective against RAS and RAF mutant tumors.

Funder

National Institutes of Health

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Susan G. Komen

Andrew Sabin Family Fellowship Program

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3